- Record: found
- Abstract: not found
- Article: not found
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer.
Raanan Alter, Gini Fleming, Walter Stadler, Akash Patnaik, R. Alter, G. FLEMING, Jens M. Stadler, A. PATNAIK, G.F. Fleming, W.M. Stadler, A Patnaik
2019
Read this article at
ScienceOpenPublisher
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.